Sign up Australia
Proactive Investors - Run By Investors For Investors

Pressure BioSciences expecting banner year for the company in 2018

Revenues for the firm's products and services increased 21% in the third quarter alone
pressure gauge
The firm speciaises in PCT (pressure cycling technology)

Pressure BioSciences Inc's (OTCMKTS:PBIO) boss Richard Schumacher expects 2018 to be a “banner year” for the firm.

In a 'Stock Day' podcast Schumacher ran through a number of aspects of recent progress, including that it had sold more PCT (pressure cycling technology) machines in the third quarter of 2017 than it had ever sold in a single quarter before.

Revenues for the firm's products and services increased 21% in that quarter alone, with consumable products increasing 158% - the largest increase in consumables the firm ever reported.

Schumacher also said a big multinational company, who was a customer, had also been working with Pressure to produce a software upgrade for its flagship Barocycler 2320EXTREME instrument.

Pressure believes this new instrument will now be "highly desirable" in its niche life sciences and pharmaceutical markets.

Also discussed was the newly established Center of Excellence in China, which will showcase three of the company's PCT instruments and many related consumable products.

"Being the first Center of Excellence in Asia, the company will focus on the Chinese biopharmaceutical and biological research markets where there is a large community of bioscience engineers and scientists and centers for biotechnology advancements," said Schumacher.

The firm's acquisition of BaroFold Inc had increased the IP (intellectual property) estate of the company by eight issued and several pending patents, and had allowed the company to offer a number of important new applications to its worldwide base of nearly 200 customers with PBIO instrumentation, he added.

Watch the Podcast HERE...

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

September 28 2018
WideCells has undertaken a review of the business to deliver a strategy that will generate revenue, reduce overheads and achieve profitability
Proton Therapy sign
October 10 2018
The broker says the cancer treatment developer could potentially take the entire share of the growth market from ageing cyclotron companies
cholesterol on a dial
September 24 2018
"The formation of ProBiotix Health and appointment of Adam Reynolds as chairman continues a successful strategy of building value in each division which is materialised by forming separate legal entities and taking them to a public listing,” said chief executive Stephen O’Hara

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2018

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use